Chengdu, China – April 8, 2026 – Full-Life Technologies ("Full-Life", the "Company"), a fully integrated clinical-stage global radiotherapeutics company, today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place in San Diego, USA from April 17 to 22, 2026. The Company will have a poster presentation.

Details of the poster are given in the table below:

About FL-261

FL-261 is a first-in-class vector for radioligand therapy treating c-MET overexpression cancers. In in-vitro assays, FL-261 shows tight binding affinity to c-MET protein with great selectivity. In tumor-bearing mice biodistribution models, radiolabeled FL-261 demonstrates high and c-MET-specific tumor uptake, with fast clearance from normal organs. Lastly, in the efficacy studies, [225Ac]Ac-FL-261 delivers promising anti-tumor activities in multiple xenograft models with low, medium and high levels of c-MET expression.  

About Full-Life Technologies

Full-Life Technologies ("Full-Life") is a fully integrated clinical-stage global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization to deliver clinical impact for patients. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals today by pioneering innovative research that will shape the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and seasoned scientists with a proven history of success in the life sciences, alongside radioisotope research and clinical development.